Current studentsExisting staffContact us
 

Frequent general practitioner visits are protective against statin discontinuation after a Pharmaceutical Benefits Scheme copayment increase

Simple item page
dc.contributor.authorSeaman, K.L.
dc.contributor.authorSanfilippo, F.M.
dc.contributor.authorBulsara, M.K.
dc.contributor.authorBrett, T.
dc.contributor.authorKemp Casey, A.
dc.contributor.authorRoughead, E.E.
dc.contributor.authorBulsara, C.
dc.contributor.authorPreen, D.B.
dc.date.issued2020
dc.description.abstractObjective This study assessed the effect of the frequency of general practitioner (GP) visitation in the 12 months before a 21% consumer copayment increase in the Pharmaceutical Benefits Scheme (PBS; January 2005) on the reduction or discontinuation of statin dispensing for tertiary prevention. Methods The study used routinely collected, whole-population linked PBS, Medicare, mortality and hospital data from Western Australia. From 2004 to 2005, individuals were classified as having discontinued, reduced or continued their use of statins in the first six months of 2005 following the 21% consumer copayment increase on 1 January 2005. The frequency of GP visits was calculated in 2004 from Medicare data. Multivariate logistic regression models were used to determine the association between GP visits and statin use following the copayment increase Results In December 2004, there were 22 495 stable statin users for tertiary prevention of prior coronary heart disease, prior stroke or prior coronary artery revascularisation procedure. Following the copayment increase, patients either discontinued (3%), reduced (12%) or continued (85%) their statins. Individuals who visited a GP three or more times in 2004 were 47% less likely to discontinue their statins in 2005 than people attending only once. Subgroup analysis showed the effect was apparent in men, and long-term or new statin users. The frequency of GP visits did not affect the proportion of patients reducing their statin therapy. Conclusions Patients who visited their GP at least three times per year had a lower risk of ceasing their statins in the year following the copayment increase. GPs can help patients maintain treatment following rises in medicines costs.
dc.identifier.citationAustralian Health Review, 2020; 44(3):377-384
dc.identifier.doi10.1071/AH19069
dc.identifier.issn0156-5788
dc.identifier.issn1449-8944
dc.identifier.urihttps://hdl.handle.net/11541.2/143493
dc.language.isoen
dc.publisherCSIRO Publishing
dc.relation.fundingNHMRC 456408
dc.rightsCopyright 2020 CSIRO Publishing Access Condition Notes: Accepted manuscript available open access
dc.source.urihttps://doi.org/10.1071/AH19069
dc.subjectdata linkage
dc.subjecthealth policy
dc.subjectout-of-pocket costs
dc.subjectprimary health care
dc.titleFrequent general practitioner visits are protective against statin discontinuation after a Pharmaceutical Benefits Scheme copayment increase
dc.typeJournal article
pubs.publication-statusPublished
ror.fileinfo12245399870001831 13245409950001831 Open Access Postprint
ror.mmsid9916412812001831

Files

Original bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
9916412812001831_12245399870001831_AM Frequent general practitioner.pdf
Size:
226.75 KB
Format:
Adobe Portable Document Format
Description:
Published version
Download

Collections